Grant Toland

1.1k total citations
5 papers, 347 citations indexed

About

Grant Toland is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Grant Toland has authored 5 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Immunology. Recurrent topics in Grant Toland's work include Cancer Immunotherapy and Biomarkers (4 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Cancer Genomics and Diagnostics (2 papers). Grant Toland is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Cancer Genomics and Diagnostics (2 papers). Grant Toland collaborates with scholars based in United States. Grant Toland's co-authors include Marisa Dolled‐Filhart, Charlotte Roach, Kenneth Emancipator, Malinka Jansson, Karina Kulangara, Nancy R. Zhang, Ellie Corigliano, Gregory M. Lubiniecki and Scot Ebbinghaus and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Archives of Pathology & Laboratory Medicine.

In The Last Decade

Grant Toland

5 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Grant Toland United States	3	310	194	59	55	47	5	347
Junliang Cai United States	9	451 1.5×	397 2.0×	65 1.1×	52 0.9×	52 1.1×	12	534
Mette Poehl Denmark	2	269 0.9×	126 0.6×	145 2.5×	43 0.8×	31 0.7×	7	318
Zhenkui Pan China	10	312 1.0×	302 1.6×	50 0.8×	80 1.5×	33 0.7×	12	423
Mélodie Tazdait France	4	229 0.7×	138 0.7×	51 0.9×	26 0.5×	46 1.0×	7	276
Miao Huang China	9	184 0.6×	159 0.8×	50 0.8×	44 0.8×	23 0.5×	17	298
Amita Mistry United States	4	214 0.7×	108 0.6×	55 0.9×	40 0.7×	44 0.9×	8	245
Prabhu Bhagavatheeswaran United States	10	384 1.2×	299 1.5×	93 1.6×	81 1.5×	30 0.6×	13	459
Frédérique Penault-Llorca France	3	270 0.9×	161 0.8×	63 1.1×	82 1.5×	28 0.6×	4	313
Zhuxing Chen China	8	231 0.7×	145 0.7×	108 1.8×	47 0.9×	46 1.0×	18	363
Ilze Bāra United States	9	260 0.8×	225 1.2×	40 0.7×	38 0.7×	37 0.8×	22	365

Countries citing papers authored by Grant Toland

Since Specialization

Citations

This map shows the geographic impact of Grant Toland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grant Toland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grant Toland more than expected).

Fields of papers citing papers by Grant Toland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grant Toland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grant Toland. The network helps show where Grant Toland may publish in the future.

Co-authorship network of co-authors of Grant Toland

This figure shows the co-authorship network connecting the top 25 collaborators of Grant Toland. A scholar is included among the top collaborators of Grant Toland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grant Toland. Grant Toland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Toland, Grant, et al.. (2021). 60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs. SHILAP Revista de lepidopterología. A68–A68. 2 indexed citations

2.

Roach, Charlotte, Nancy R. Zhang, Ellie Corigliano, et al.. (2016). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer. Applied immunohistochemistry & molecular morphology. 24(6). 392–397. 249 indexed citations

3.

Dolled‐Filhart, Marisa, Charlotte Roach, Grant Toland, et al.. (2016). Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. Archives of Pathology & Laboratory Medicine. 140(11). 1243–1249. 86 indexed citations

4.

Dolled‐Filhart, Marisa, Scot Ebbinghaus, Charlotte Roach, et al.. (2016). Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9571–9571. 2 indexed citations

5.

Dolled‐Filhart, Marisa, et al.. (2015). Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). 11065–11065. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact